Drugs / Drotrecogin alpha
Drotrecogin alpha
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00943267 | Oct 2008 → Aug 2010 | pneumonia | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Drotrecogin alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00943267 ↗ |
| Known as | Activated Protein C | “Recombinant human Activated Protein C (rhAPC) has been shown to reduce the mortality of patients with severe sepsis.” NCT00943267 ↗ |
| Known as | rhAPC | “Recombinant human Activated Protein C (rhAPC) has been shown to reduce the mortality of patients with severe sepsis.” NCT00943267 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human Activated Protein C (rhAPC)” NCT00943267 ↗ |
| Route | Other | “Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0” NCT00943267 ↗ |